AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 41 min read$SYRE

Turtle Cameron sold $1.3M of SYRE

Turtle Cameron (Chief Executive Officer) sold 15,000 shares of Spyre Therapeutics, Inc. (SYRE) at an average of $87.29 ($86.36–$89.07, $1.31M total) across 4 trades on 2026-09-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Turtle Cameron
Published Sep 4, 2026, 1:33 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 1:35 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$SYRE
Bearish
medium confidence
Mentioned
$SYRE
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SYREBearishLow
01

Why it matters

The disclosed sale reduces insider ownership but does not materially alter control; market reaction likely muted.

02

Market read

Primary insider sale news; modest relevance for traders holding or shorting SYRE.

03

What to watch

Potential upcoming clinical data releases or financing activities could offset the negative signal.

Relevance 5/10Novelty 7/10Timing: filed after market close on 2026-09-03

Background

Form 4 filings disclose insider transactions; investors monitor them for signals about management confidence.

Company-level read

Ticker impact

$SYREBearishMedium confidence
Context

CEO Turtle Cameron sold 15,000 shares for $1.3M via a 10b5-1 plan, reducing his stake to 552,540 shares.

Expected impact

Possible modest downside pressure over the next few days.

Evidence & confidence

The sale size is modest relative to float, but the CEO is a key insider; market may interpret the transaction as a negative signal.

Market effects

Sector

Minimal impact on biotech sector; insider sales are company‑specific.

Regional

No broader regional effect.

Global

Limited to investors tracking Spyre Therapeutics.

Counterpoint

What could challenge this read

The sale could be a routine liquidity event unrelated to company outlook; price may remain stable.

Key entities

  • person
    Turtle Cameron

    Chief Executive Officer of Spyre Therapeutics, Inc.

  • company
    Spyre Therapeutics, Inc.

    Biotech firm developing therapies; ticker SYRE.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

SYRE insider trading history →

Related articles

SEP 17
$SYREMedAI 9/10

Spyre (SYRE) Clears Monotherapy Phase for IBD Portfolio, Setting Up Combination Tests

Spyre Therapeutics (SYRE) reported that its anti-IL-23 antibody, SPY003, met primary endpoints in a Phase 2 trial, showing a 10.0-point reduction in Robart’s Histopathology Index score. This follows successful results for SPY001 and SPY002, completing proof-of-concept for all three molecules in its IBD portfolio. The company has $1.1 billion in cash, enough to fund operations into 2029. Part B of the SKYLINE trial, testing drug combinations, is still enrolling, with data expected in 2027. Spyre

insidermonkey.com2 min
SEP 11
$SYREMedAI 8/10

Spyre Therapeutics (SYRE) Reports SPY003 Endoscopic Improvement. Can Randomized Testing Confirm It?

Spyre Therapeutics (SYRE) reported Phase 2 trial results for SPY003 in ulcerative colitis patients, showing a 10-point decline in tissue inflammation and 20% clinical remission. The study lacked a control arm, and further testing is needed. The company has $1.15B in cash and expects funding into 2029. Part B of the trial is enrolling, with results expected in 2027.

insidermonkey.com2 min
AUG 27
$SYREMedAI 8/10

Top Biotechnology Stock Pick from Guggenheim

Guggenheim maintains a buy rating on Spyre Therapeutics, citing positive Phase II SKYWAY-RA results for SPY072, despite discontinuing the rheumatoid arthritis program. The firm projects the stock to settle in the $90-95 range, with valuation based on the inflammatory bowel disease program. Other analysts have mixed views, with Wolfe Research downgrading and Mizuho raising its price target to $120.

investing.com2 min
AUG 26
$SYREHighAI 8/10

Why is Spyre Therapeutics stock sliding today?

Spyre Therapeutics (SYRE) stock fell 11.7% in pre-market trading after Phase 2 trial data for SPY072 in rheumatoid arthritis showed statistically significant but insufficient efficacy to advance as a monotherapy. Wedbush maintained an Outperform rating with a $130 target. The company plans further readouts in 2026 for other indications. The decline is attributed to the clinical news, not broader market trends.

investing.com2 min